Compare Capital One Financial Corp. (COF) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Capital One Financial Corp. vs Crispr Therapeutics AG — how do they compare? Capital One Financial Corp. trades at $219.37 (market cap $134.45B), while Crispr Therapeutics AG trades at $54.1 (market cap $5.23B). The key difference: Capital One Financial Corp. is far larger — about 25.7× Crispr Therapeutics AG's market cap, and Capital One Financial Corp. pays a 1.46% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| COF | CRSP | |
|---|---|---|
Market Cap | $134.45B | $5.23B |
Sector | Financials | Health |
52-Week High | $257.94 | $76.78 |
52-Week Low | $176.10 | $44.34 |
Dividend Yield | 1.46% | — |
Enterprise Value | — | $3.65B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Capital One Financial Corp.
Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending.
Read more on COF →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
